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Abstract 17 
Background:  Several observational studies were published investigating the association 18 
between oral fluoroquinolone use and the development of retinal detachment; however, the 19 
findings are not concordant. This study is a meta-analysis of the existing literature and estimates 20 
the overall absolute risk of such an event. 21 
Methods: Electronic databases were searched for observational studies on the association 22 
between oral fluoroquinolone and retinal detachment up to August 2014. Studies that did not 23 
meet the criteria for meta-analysis were narratively reviewed. Cases of retinal detachment during 24 
current fluoroquinolone use were also extracted for absolute risk calculation.  25 
Results: Seven observational studies were included. Three (case-control and self-controlled case 26 
series studies) were eligible for meta-analysis and four (cohort studies) were narratively 27 
reviewed. The rate ratio of the case-control studies was 1.82 (95% CI 0.67-4.93), I2=96% and the 28 
incidence rate ratio of the self-controlled case series was 1.03 (95% CI 0.84-1.27), I2=36%. 29 
Three of the four cohort studies found no significant association between oral fluoroquinolone 30 
use and the development of retinal detachment. The pooled absolute risk of retinal detachment 31 
whilst on current oral fluoroquinolone treatment is estimated to be 4.85 per 1,000,000 32 
prescriptions (95% CI 0.78 – 8.91).  33 
Conclusion:  The findings of this systematic review and meta-analysis do not support an 34 
association between oral fluoroquinolone use and the development of retinal detachment. Given 35 
the low absolute risk, such an event would be rare if there were an association. The current 36 
prescribing practice for fluoroquinolones should not be altered because of a previously suggested 37 
potential risk of retinal detachment. 38 
Introduction  39 
 Etminan et al.1 reported a significant association between the current use of oral 40 
fluoroquinolones (FQ) and the development of retinal detachment (RD) (i.e. an RD event 41 
occurring within the prescription period of FQ). This study caused the US, Canadian and 42 
European regulatory authorities to place FQ on their alert list2-4 and since then more 43 
observational studies have been published. This systematic review and meta-analysis evaluates 44 
these observational studies and the potential for increased risk of RD with oral FQ use. 45 
Method 46 
A systematic literature search was conducted using keywords, MeSH and Emtree terms. 47 
Records were retrieved from databases including Pubmed, CINAHL and EMBASE in August 48 
2014.The search terms included were fluoroquinolones AND (retinal detachment OR retinal*). 49 
This study was conducted in accordance with the Preferred Reporting Items for Systematic 50 
reviews and Meta-Analyses (PRISMA)5 and the Meta-analysis of Observational Studies in 51 
Epidemiology6 to ensure clear and comprehensive reporting. 52 
Inclusion and exclusion criteria 53 
Observational studies that investigated the association between FQ use and the 54 
development of RD were included. Animal studies were excluded.  55 
Quality assessment 56 
The included studies were assessed for methodological quality using the Newcastle-57 
Ottawa Scale (NOS) as recommended by the Cochrane Collaboration.7 CSLC and LYLW 58 
independently reviewed and scored each of the studies. Study quality is indicated by the number 59 
of stars with a maximum allocation of 9 stars. 60 
Data extraction 61 
Data on the outcome of interest, which is the risk or odds of developing RD whilst on FQ 62 
treatment, were extracted for analysis. Statistics presenting the period up to 10 days from the first 63 
day of prescription were selected. Studies where such statistics could not be extracted or 64 
included in the meta-analysis were summarised in the narrative review.  65 
Statistical analysis 66 
A random-effects model8 was used in the meta-analysis to account for heterogeneity 67 
between studies. Statistical analyses were conducted using Review Manager 5.2 (Cochrane 68 
Collaboration, 2012).  69 
The number of RD cases that occurred whilst on FQ treatment was extracted from the 70 
original list of articles and the absolute risk was estimated using a method previously described.9 71 
The 95% CI was calculated using the Wilson score interval.10 The analysis was performed using 72 
SAS 9.3 (SAS Inc, USA).   73 
Results 74 
A total of 695 citations were retrieved from the literature search. CSLC and LYLW 75 
screened and reviewed relevant articles independently. Seven observational studies were relevant 76 
(Figure 1). The quality of the methodology was assessed and the results are presented in Table 1 77 
and 2.  78 
Case-control  79 
Two case-control studies were included in the meta-analysis. Etminan et al.1 reported a 80 
positive association between FQ use and the development of RD in a cohort, nested among 81 
patients who had visited an ophthalmologist, using The British Columbia Linked Health 82 
Database.11 Cases were defined as those with an RD-related procedure 14 days after the 83 
diagnosis date. Cases in FQ users and non-FQ users were compared and the rate ratio (RR) was 84 
adjusted for sex, previous history of cataract surgery, myopia, diabetes, number of visits to 85 
ophthalmologist, and number of prescription drugs used. In an attempt to replicate the study of 86 
Etminan et al., Fife et al.12 conducted a similar analysis in the US using the MarketScan 87 
Commercial Claims and Encounters and the Optum ClinFormatics database. The results are 88 
presented as Fife 2014 (CCAE-CC) and Fife 2014 (Optum-CC) respectively in the meta-analysis. 89 
Meta-analysis of the three databases did not show a significant association with an odds ratio 90 
(OR) of 1.82(95% CI 0.67-4.93), I2=96% (Figure 2). There was no significant change to the RR 91 
[1.25(95%CI 0.95-1.65)], I2 of 0%, following removal of Etminan et al. study from the 92 
sensitivity analysis.  93 
Self-controlled case series 94 
Two studies using four different databases were included in this meta-analysis. Neither 95 
study found a significant association between oral FQ use and the development of RD. Of these, 96 
one study9 was done using the Hong Kong Clinical Data Analysis and Reporting System 97 
(CDARS) and Taiwan National Health Insurance Research Database (NHIRD). The incident RR 98 
(IRR) was adjusted for age, history of diabetes and cataract surgery. The meta-analysis results of 99 
Hong Kong and Taiwan database are presented as Chui 2014 (HK) and Chui 2014 (TW), 100 
respectively. Fife et al.12 also conducted a self-controlled case series study in the US. Unlike the 101 
case-control analysis, ophthalmology visits were not an inclusion criterion. Cases were defined 102 
as those with RD 30 days after the beginning of FQ exposure. The RRs are presented as Fife 103 
2014 (CCAE-SCCS) and Fife 2014 (Optum-SCCS). Meta-analysis of the four databases gave a 104 
statistically non-significant IRR of 1.03(95% CI 0.84-1.27), I2=36% (Figure 3). 105 
Narrative review 106 
Four cohort studies13-16 were also included in this review. However, their study designs 107 
were very different and therefore, are not appropriate for meta-analysis.  108 
Pasternak et al.13 used the Central Person Register to identify adults living in Denmark 109 
from 1997 to 2011. RD cases were defined as incident diagnosis of RD with a related procedure 110 
performed within 14 days of the diagnosis date. They reported 5 cases of RD among current FQ 111 
users (1-10 days post first day of treatment) with a corresponding RR of 1.29(95% CI 0.53-3.13) 112 
compared to non-FQ use. RR for recent use (11-30 days) was 0.97(95%CI 0.46-2.05), past use 113 
(31-60 days) was 1.37(95% CI 0.80-2.35) and distant use (61-180 days) was 1.27(95% CI 0.93-114 
1.75). The crude incidence rate was 25.3 cases per 100,000 person-years in current users. The 115 
authors concluded that oral FQ use was not associated with an increased risk of RD.  116 
Kuo et al.14 identified FQ and amoxicillin users from the NHIRD between 1998 and 2010. 117 
They compared FQ users with amoxicillin users and estimated an adjusted hazard ratio (HR) of 118 
2.07(95% CI 1.45-2.96) in a 90 day follow-up period. The adjusted HR was 10.68(95% CI 3.28-119 
34.82) for ciprofloxacin, 2.41(95% CI 0.76-7.68) for levofloxacin, 2.00(95% CI 1.06-3.79) for 120 
norfloxacin, 1.17(95% CI 0.59-2.31) for ofloxacin and 1.48(95% CI 0.25-8.84) for lomefloxacin. 121 
The median interval between the beginning of the FQ prescription and the index date of RD 122 
diagnosis was 35.5 days. RD cases were defined as diagnosis with RD within 90 days of the 123 
follow-up period. The authors concluded that oral FQ was associated with subsequent occurrence 124 
of RD. The FQ risk was independent of age, sex, diabetes, indications for antimicrobials, and 125 
underlying ophthalmic conditions. 126 
Kapoor et al.15 examined whether there was an associated increase in subsequent RD and 127 
symptomatic retinal breaks and oral FQ. They included adult residents of Olmsted County, 128 
Minnesota, who were prescribed oral FQ from 2003 to 2011, from the Rochester Epidemiology 129 
Project. Patients prescribed oral FQ were compared to those prescribed oral macrolide and β-130 
lactam antibiotics. Cases were defined as procedures recorded within 1 year of the first 131 
prescription. RD repair procedures were performed within 365 days of the first prescription in 132 
0.03% (95% CI 0.01-0.06) of the FQ group, 0.02% (95% CI 0.01-0.03) of the macrolide group, 133 
and 0.03% (95% CI, 0.02-0.05) of the β-lactam group (P>0.05). There were no significant 134 
differences in treatment rates within 7, 30, and 90 days of the first prescription between the 135 
groups. Kapoor et al.15 concluded that oral FQ use was not associated with an increased risk of 136 
RD or symptomatic retinal breaks in their study.  137 
Eftekhari et al.16 investigated whether oral FQ use would increase the risk of RD and 138 
retinal tear in the UK using The Health Improvement Network database (THIN). Patients 139 
prescribed FQ between 1994 and 2012 were compared with those prescribed β-lactam. Cases 140 
were defined as those with a procedure related to retinal break during the observation period. No 141 
case was observed 7 days after the prescription among FQ users; therefore it was not possible to 142 
estimate the HR. The adjusted HR was 0.78 (95% CI 0.02-4.74) 30 days after prescription, 1.26 143 
(95% CI 0.40-3.06) at 90 days, and 1.35 (95% CI 0.85-2.06) at 365 days. A sensitivity analysis 144 
included only cases with a retinal break diagnosis within 30 days of the procedure with no 145 
findings of increased risk. Eftekhari et al.16 concluded that no increased risk of retinal break was 146 
observed using the THIN database.  147 
Absolute risk of RD whilst on current FQ treatment 148 
The absolute risks of developing RD whilst on current FQ treatment among the included 149 
studies are presented in Table 2. No RD cases in current FQ users were reported in Kapoor et 150 
al.15 and Eftekhari et al.16 The total number of FQ prescriptions was not reported by Etminan et 151 
al.1 and Fife et al.;12 therefore the absolute risk cannot be estimated. The pooled absolute risk of 152 
the five database analyses is estimated to be 4.85 per 1,000,000 prescriptions (95% CI 0.78–8.91) 153 
(Figure 4). 154 
Discussion 155 
The results of this meta-analysis do not support an association between oral FQ use and 156 
the development of RD. Three of the four cohort studies13, 15, 16 in the narrative review do not 157 
support an association either. Although two studies1, 14 reported significant results, they do not 158 
concur. Etminan et al.1 reported that the effect of FQ on RD is of an acute nature, i.e. current FQ 159 
users. However, Kuo et al.14 report that the median interval between the prescription and the 160 
index date of RD diagnosis was 35.5 days, i.e. not acute.  161 
Farioli and Kriebel17 estimated the incidence rate of RD in the study of Kuo et al.14 to be 162 
218.5 per 100,000 patient-years with a mean age of 47 years. The incidence of RD is age-163 
dependent with <19–27 cases per 100,000 person-years in the sixth decade of life18. They 164 
questioned the validity of the findings of Kuo et al.since the study’s incidence rate was much 165 
higher with a lower mean age. This discrepancy may be explained by significant differences in 166 
the RD case definition in the study of Kuo et al.,14 where procedure codes were not required to 167 
confirm RD cases.  168 
It is worth noting that the RR reported by Etminan et al.1 was much higher than that 169 
reported by other included studies. Fife et al.12 replicated the analysis using two datasets from 170 
two databases and estimated an OR of almost 1. Since both studies had similar settings, it is 171 
unclear why this discrepancy occurred. However, differences in clinical practice and the coding 172 
system may account for this. Fife et al.12 validated their results with additional analyses; however, 173 
they did not find a significant association, which concurs with the findings of this meta-analysis. 174 
The meta-analysis for self-controlled case series gave an RR of almost 1 [1.03(95% CI 175 
0.84-1.27)] with moderate variability among the studies from different countries (I2=36%). With 176 
such a narrow confidence interval around 1, the results clearly reject an association between the 177 
use of FQ and RD. Finally, it is important to note that the pooled absolute risk of developing RD 178 
whilst on FQ treatment was minimal (Figure 4). Such an event would be very rare if there were 179 
an association.  180 
Strength and limitation 181 
Disease codes such as ICD-9 were used to identify cases among the included studies. 182 
Although the case definitions varied, all (except Kuo et al.14) included a procedure code to 183 
confirm the RD case. The codes of the included databases have been validated in other 184 
settings,19-21 thus ensuring the quality of the analysed data. In addition, the study designs of all 185 
the included studies are of satisfactory quality, obtaining more than 6 of 9 stars from the NOS 186 
quality assessment. 187 
The results of this meta-analysis are compiled from available observational studies and 188 
attempts to draw a conclusion on the potential for increased risk of RD with oral FQ use. 189 
Variability may have an effect on heterogeneity, which is demonstrated in the meta-analysis of 190 
the case-control studies. However, the result remains non-significant in the sensitivity analysis 191 
with reduced heterogeneity. Furthermore, the heterogeneity of the self-controlled case series 192 
studies analyses was not significant and supports the validity of the conclusion. 193 
Conclusion 194 
The results of the meta-analysis do not support an association between oral FQ use and 195 
the development RD. However, if there were an association, such events would be rare given the 196 
small absolute risk estimated in the available literature. Based on the evidence from this meta-197 
analysis, the use of oral FQ should not be precluded.  198 
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Table 1. Study characteristics and quality 
Study Data Source 
Study 
period Region Study design 
Inclusion 
criteria 
Exclusion 
criteria 
Outcome 
definition 
Newcastle-Ottawa Scalea,b 
Selection Comparability Exposure/Outcome 
Etminan 
20121 
British 
Columbia 
Linked Health 
Database 
01/2000-
12/2007 
Canada CC Had an 
ophthalmologist 
visit 
History of RD 
diagnosis or 
procedures; 
endophthalmitis; 
intravitreal 
injection or 
vitreous biopsy 
RD procedure 
(British Columbia 
procedure codes) 
received within 14 
days after RD 
diagnosis (ICD-9) 
* ** *** 
Kuo 201314 NHIRD 1998-2010 Taiwan C Aged >18 years; 
prescribed >3 
consecutive 
doses of oral 
FQ/amoxicillin 
Treated with FQ 
or amoxicillin 
during the prior 
90 days; 
hospitalised 90 
days prior to 
enrollment; 
history of RD 
diagnosis or 
procedure; 
blindness; 
procedure for 
encleation or 
evisceration of 
eyes 
RD diagnosis 
(ICD-9) within 90 
days of follow-up 
*** ** *** 
Pasternak 
201313 
Central 
Person 
Register, The 
National 
Prescription 
Registry, The 
Danish 
National 
Patient 
Registry 
1/1/1997-
31/12/2011 
Denmark C Aged ≥18 years; 
prescribed FQ; 
no history of RD 
or retinal break; 
did not use FQ in 
the last 180 days; 
had lived in 
Denmark for 
minimum of 2 
years; had filled 
at least 1 
prescription for 
History of 
endophthalmitis, 
intravitreal 
injection, or 
choroidal; retinal 
or vitreal biopsy; 
cataract surgery; 
major eye 
surgery or eye 
trauma 30 days 
before RD 
RD procedure 
received within 14 
days after RD 
diagnosis 
**** ** *** 
any medication 
in the last year; 
no history of 
hospitalisation in 
the last 30 days 
Chui 20149 CDARS, 
NHIRD 
HK: 
1/1/2001-
31/12/2012 
Taiwan: 
1/1/2000-
31/12/2010 
HK, 
Taiwan 
SCCS Prescribed FQ Head or eye 
injury 30 days 
before RD; 
history of 
endophthalmitis, 
RD diagnosis or 
procedure.  
RD procedure 
during FQ 
prescription (ICD-
9) 
*** ** *** 
Eftekhari 
201416 
THIN 06/1994-
01/2012 
UK C Had prescription 
for FQ or β-
lactam; 
registered with 
GP for at least 
365 consecutive 
days prior 
prescription date 
History of RD or 
retinal tear; FQ 
and β-lactam 
prescribed on the 
same day; 
history of 
intraocular 
surgery or 
diagnosis of 
endophthalmitis 
within 90 days of 
prescription. 
RD or retinal tear 
procedure 
(Medcodes) 
within 7, 30, 90 
and 365 days after 
the FQ 
prescription 
**** * *** 
Fife 
201412c 
CCAE, 
Optum 
CCAE: 
1/1/2000-
31/1/2012 
Optum: 
1/9/2005-
31/3/2012 
USA CC Had an 
ophthalmologist 
visit and at least 
1 year in the 
cohort 
History of RD 
diagnosis or 
procedure; 
endophthalmitis 
or related 
procedures such 
as vitreous 
biopsy or 
intravitreal 
injection; RD 
event happened 
during 
hospitalisation or 
within 10 days 
after being 
discharged 
RD procedure 
received within 14 
days after RD 
diagnosis 
* ** *** 
SCCS Ophthalmologist 
visit not required 
Exclusion 
criteria in CC; 
history of 
inflammatory, 
infectious, or 
traumatic 
retinitis; index 
date of RD event 
happened during 
current or recent 
use of multiple 
antibiotic 
prescription (FQ 
and/or β-lactam); 
hospitalisation 
between cohort 
entry and event 
date 
Restricted to 
codes associated 
with 
rheumatogenous 
retinal detachment 
and within 30 
days after the 
beginning of FQ 
prescription 
*** ** *** 
Kapoor 
201415 
REP 1/1/2003-
30/6/2011 
USA C Prescribed FQ, 
macrolides or β-
lactam 
History of 
endophthalmitis, 
necrotising 
retinitis, 
ipsilateral 
intraocular 
surgery; severe 
ocular/head 
trauma within 90 
days of RD; 
treated with 
serous/ exudative 
retinal 
detachment or 
diabetic 
retinopathy-
related tractional 
RD. 
RD procedure 
(Current 
Procedure 
Terminology) 
within 7, 30, 90 
and 365 days after 
the FQ 
prescription  
**** * *** 
Abbreviations: CC=Case-control study; RD=retinal detachment; ICD-9= International Classification of Diseases, Ninth Revision; 
NHIRD=National Health Insurance Research Database; C=Cohort study; FQ=fluoroquinolones; CDARS=Clinical Data Analysis and Reporting 
System; HK=Hong Kong; SCCS=Self-controlled case series; THIN=The Health Improvement Network; UK=United Kingdom; 
CCAE=MarketScan Commercial Claims and Encounter database; Optum=Optum ClinFormatics database; USA=United States of America; 
REP=Rochester Epidemiology Project. 
a Quality assessment of the methodology of the included studies. The assessment guideline for case-control studies was used for self-controlled 
case series studies. 
b Study quality was indicated by a higher number of stars. Each study could be allocated a maximum of 9 stars. 
c Replication case-control and self-controlled case series analyses.
Table 2. Summary of the results of included studies and estimated absolute risk 
Study Sample size  Closest “Current use” definition 
Number of 
cases in 
“current FQ 
use” 
Result of current FQ use 
Absolute risk of RD whilst on FQ 
treatment (up to 10 days from the first 
day of prescription)a 
Etminan 
20121 
RD case: 4,384 
Control: 43,840 
Within prescription 
period 
145 Rate Ratio: 
4.50(95% CI 3.56-5.70) 
Data not available 
Kuo 201314 FQ  prescriptions: 
178,179  
AMX  
prescriptions: 
178,179  
Patients were 
followed up for 90 
days after they entered 
the cohort 
96 Hazard Ratio:  
2.07(95% CI 1.45-2.96) 
Data not available  
Pasternak 
201313 
FQ episodes: 
748,792 
Control episodes: 
5,520,446 
1-10 days starting 
from the first day of 
prescription 
5 Rate Ratio: 
1.29(95% CI 0.53-3.13) 
5 cases out of 748,792 prescriptions 
=6.7 per 1,000,000 prescriptions 
 
Chui 20149 FQ prescriptionsb: 
HK: 
260,198 
TW:  
1,098,086  
Within prescription 
period 
HK: 2b 
TW: 7b 
Incidence rate ratio: 
HK: 0.82(95% CI 0.20-3.36) 
TW: 1.45(95% CI 0.68-3.10) 
HK: 2 cases out of 260,198 prescriptions 
=7.7 per 1,000,000 prescriptions 
TW: 7 cases out of 1,098,086 prescriptions 
=6.4 per 1,000,000 prescriptions 
 
Eftekhari 
201416 
FQ prescriptions: 
290,393 
β-lactam 
prescriptions: 
6,314,030 
1-7 days after the 
prescription 
0 Data not available  0 case out of 290,393 prescriptions 
Fife 201412c Case control: 
CCAE: 
RD case: 7,844 
Control: 77,654 
Optum: 
RD case: 3,059 
Control: 30,230 
 
Self-controlled case 
series (case only): 
CCAE: 19,101 
Optum: 6,896 
Case control: 
Within prescription 
period 
 
Self-controlled case 
series: 
30 days after start of 
FQ prescription 
Case control: 
CCAE: 66 
Optum: 13 
 
Self-controlled 
case series: 
CCAE: 74 
Optum: 18 
Odds ratio (Case control): 
CCAE: 1.33(95% CI 0.99-1.80) 
Optum: 0.93(95% CI 0.48-1.81) 
 
Rate Ratio (Self-controlled case 
series): 
CCAE: 1.13(95% CI 0.99-1.29) 
Optum: 0.85(95% CI 0.66-1.09) 
Data not available 
Kapoor 
201415 
 
FQ prescriptions:  
92,130 
Macrolide 
prescriptions: 
107,086 
β-lactam 
prescriptions: 
178,352 
Within 7 days after 
the prescription 
0 0%(95% CI 0-0.01)  0 case out of 92,130 prescriptions 
 
 
 
 
 
Overall 
absolute 
risk 
    4.85 case out of 1,000,000 prescriptions 
(95% CI 0.78-8.91) 
Abbreviations: FQ=fluoroquinolones; RD=retinal detachment; AMX=Amoxicillin; HK=Hong Kong; TW=Taiwan; CCAE=MarketScan 
Commercial Claims and Encounters database; Optum=OptumClinFormatics database. 
a Absolute risk of RD whilst on FQ treatment = number of RD cases whilst on FQ treatment divided by total number of FQ prescriptions included 
in the study  
b Unpublished data, requested from authors 
c Replication case-control analysis 
 
 
 
 
 
 
 
 
 
 
Figure legend: 
Figure 1. PRISMA flowchart 
Figure 2. Meta-analysis of case-control studies 
Figure 3. Meta-analysis of self-controlled case series studies 
Figure 4. Meta-analysis of absolute risk of retinal detachment whilst on oral fluoroquinolone treatment
 Figure 1. PRISMA flowchart
Figure 2. Meta-analysis of case-control studies 
Figure 3. Meta-analysis of self-controlled case series studies 
 
 Figure 4. Meta-analysis of absolute risk of retinal detachment whilst on oral 
fluoroquinolone treatment 
Abbreviations: RD=retinal detachment; FQ=oral fluoroquinolones; CL=confidence Limit; AR=absolute 
risk; LCL=Lower 95% Confident Limit; UCL=Upper 95% Confident Limit; HK=Hong Kong; 
TW=Taiwan. 
